StentGuard Clinical validation of the First Implantable Sensor System for Wireless detection of stent occlusion/ restenosis
- Coordinator
- Vesselsens GmbH, Germany
- Runs
- 1 October 2022 to 31 July 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €11.3m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190107486
What the project is doing
In the project's own words, from its summary on CORDIS.
Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implanted worldwide every year. Restenosis, the gradual reclogging of the blood vessel after stent implantation, is a major problem leading to high morbidity and mortality which occurs within 6 years after implantation in ~23 % of all cases and is often detected when it is too late.
More frequent surveillance of PAD patients to avoid unnecessary amputations and death is an unmet clinical challenge. VesselSens is developing the StentGuard, a smart therapeutic monitoring device that enables rapid, low cost, early diagnosis of restenosis non-invasively and reliably. This device allows stent monitoring at high frequencies with low cost by non-specialist medical practitioners solving the problem of unchecked disease progression and saving the EU economy over €1bn/ year.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Vesselsens GmbH | Bonn | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI